文献速递血栓与止血

儿童2019冠状病毒病与儿童多系统炎症综合征中的血栓并发症

Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood.
PubMed 文献 · J Thromb Haemost · 2023-06-01

本文为叙述性综述,讨论COVID-19相关凝血病的推测病理生理机制,总结成人抗血栓治疗随机试验的主要发现,汇总儿童COVID-19与儿童多系统炎症综合征(MIS-C)中静脉血栓栓塞和缺血性卒中的研究数据,并回顾唯一一项非随机儿童预防性抗凝安全性试验及成人和儿童共识指南。

要点

  • COVID-19相关凝血病涉及炎症驱动的高凝状态、内皮功能障碍、血小板激活和纤溶受损。
  • 住院COVID-19成人静脉血栓栓塞和缺血性卒中风险增加,儿童虽病程较轻但动脉和静脉血栓均有报告。
  • MIS-C与高凝状态和血栓形成相关,儿童抗血栓治疗数据缺乏,仅有唯一一项非随机试验。

核心结论

  • 儿童COVID-19和MIS-C均可发生动脉和静脉血栓形成,但儿童抗血栓治疗数据缺乏,仅有唯一一项非随机试验评估预防性抗凝安全性。

研究设计与样本

  • 叙述性综述,讨论COVID-19凝血病的推测病理生理机制,总结成人抗血栓治疗随机试验的主要发现,汇总儿童COVID-19和MIS-C中静脉血栓栓塞和缺血性卒中的研究数据,并回顾唯一一项非随机儿童预防性抗凝安全性试验及成人和儿童共识指南。

主要发现

  • COVID-19相关凝血病为多因素,涉及炎症驱动的高凝状态、内皮功能障碍、血小板激活和纤溶受损。
  • 住院COVID-19成人静脉血栓栓塞和缺血性卒中风险增加,导致不良结局包括死亡率增加。
  • 儿童COVID-19病程较轻,但住院患儿中动脉和静脉血栓均有报告。
  • 部分儿童发生感染后高炎症性疾病MIS-C,也与高凝状态和血栓形成相关。
  • 多项随机试验评估了成人COVID-19抗血栓治疗的安全性和有效性,但缺乏类似儿童数据。

局限性

  • 儿童抗血栓治疗数据缺乏,仅有唯一一项非随机儿童预防性抗凝安全性试验。
  • 已发表数据的实际实施和当前局限性有待详细讨论,以弥补儿童COVID-19抗血栓治疗的知识缺陷并提出未来研究假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet activation, and impaired fibrinolysis. Hospitalized adults with COVID-19 are at an increased risk of both venous thromboembolism and ischemic stroke, resulting in adverse outcomes, including increased mortality. Although COVID-19 in children follows a less severe course, both arterial and venous thromboses have been reported in hospitalized children with COVID-19. Additionally, some children develop a postinfectious, hyperinflammatory illness termed multisystem inflammatory syndrome of childhood (MIS-C), which is also associated with hypercoagulability and thrombosis. Several randomized trials have evaluated the safety and efficacy of antithrombotic therapy in adults with COVID-19, although similar pediatric data are lacking. In this narrative review, we discuss the postulated pathophysiology of COVID-19 coagulopathy and summarize principal findings of the recently completed adult trials of antithrombotic therapy. We provide an up-to-date summary of pediatric studies investigating the rate of venous thromboembolism and ischemic stroke in COVID-19 and multisystem inflammatory syndrome of childhood in addition to reviewing the findings of the single, nonrandomized pediatric trial investigating the safety of prophylactic anticoagulation. Lastly, we outline adult and pediatric consensus guidelines on the use of antithrombotic therapy in this cohort. A detailed discussion of the practical implementation and current limitations of published data will hopefully address the knowledge deficits surrounding the use of antithrombotic therapy in children with COVID-19 and generate hypotheses for future research.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kumar R, Rivkin MJ, Raffini L, et al. Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood. J Thromb Haemost. 2023. PMID: 37268064. doi:10.1016/j.jtha.2023.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。